Boston Advisors’s Moderna MRNA Stock Holding History

Boston Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$283K	Buy	+17,793	New	+$263K	0.01%	525

Other funds holding MRNA

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

RWA

Ropes Wealth Advisors Boston, Massachusetts $515M AUM 21.76% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Boston Advisors's MRNA Position: Q3 2019 in Review

Boston Advisors opened a new position in Moderna (MRNA) in Q3 2019: 17,793 shares worth $283K. The stake represents 0.01% of the portfolio and ranks #525 among its holdings.

136 funds tracked by Wall St. Rank hold MRNA as of Q3 2019.

Boston Advisors held 17,793 shares of Moderna worth $283K as of Q3 2019.
Moderna was a new Boston Advisors position in Q3 2019.
Moderna made up 0.01% of Boston Advisors's portfolio in Q3 2019, its #525 holding.
136 funds tracked by Wall St. Rank held Moderna as of Q3 2019.

Based on Boston Advisors's 13F filing for Q3 2019, filed 5 Nov 2019.